NLRP3 and cystic fibrosis: Inhibition of IL-1β via antibody neutralization [43], small molecule NLRP3 inhibitors including MCC950 [40], inhibition of the epithelial sodium channel-NLRP3 axis [49], or by the IL-1Ra agonist Anakinra [46], ameliorates inflammasome-associated inflammation in models of CF via negative regulation of pathogenic NLRP3 activity.